Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.

Hu-Lieskovan, Siwen; Malouf, Gabriel G; Jacobs, Ira; Chou, Jeffrey; Liu, Li; Johnson, Melissa L

Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.

Hu-Lieskovan, Siwen; Malouf, Gabriel G; Jacobs, Ira; Chou, Jeffrey; Liu, Li; Johnson, Melissa L.

Affiliation

Hu-Lieskovan S; Department of Medicine, Division of Oncology, Huntsman Cancer Institute / University of Utah, Salt Lake City, UT 84112, USA.
Malouf GG; Department of Medical Oncology, Institut de Cancérologie de Strasbourg & Department of Functional Genomics & Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/UNISTRA, Illkirch Cedex, Strasbourg, France.
Jacobs I; Pfizer Inc, New York, NY 10017, USA.
Chou J; Pfizer Inc, San Diego, CA 92121, USA.
Liu L; Pfizer Inc, San Diego, CA 92121, USA.
Johnson ML; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA.

Future Oncol ; 17(11): 1401-1439, 2021 Apr.

Article in En | MEDLINE | ID: mdl-33475012

Subject(s)

Drug Resistance, Neoplasm; Immune Checkpoint Inhibitors/therapeutic use; Antigens, Neoplasm/immunology; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Humans; Mutation; Neoplasms/drug therapy; Neoplasms/genetics; Neoplasms/immunology; Signal Transduction/drug effects; Signal Transduction/immunology; Tumor Microenvironment/drug effects; Tumor Microenvironment/immunology

Key words

clinical trials; cytotoxic T-lymphocyte antigen-4; immune checkpoint inhibitor; mechanism; preclinical; programmed cell death protein 1; resistance

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Resistance, Neoplasm / Immune Checkpoint Inhibitors Type of study: Prognostic_studies Limits: Humans Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google